small molecule

HYRNUO

SEVABERTINIB

Loss of exclusivityOctober 2035latest FDA-listed patent expiry

CompanyBayer Healthcare →See this company's full patent-cliff portfolio

Drug detail

Brand name	HYRNUO
Active ingredient	SEVABERTINIB
Strength	10MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	November 2025
Marketing status	RX

Listed patents

Patent	Expires	Type
10428063	October 2035	substance, product

Regulatory exclusivity

Code	Expires
NCE	November 2030

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Bayer Healthcare